Eric Sandor is an inspirational leader with a track record of pioneering new businesses and delivering transformational change within the Health and Life Sciences sectors. He brings broad and deep experience gained over 30 years across strategy, operations, technology, organisational restructuring and operating models within the Life Sciences industry. He is passionate about innovating new products, creating AI-enabled services and value propositions, building high performing teams, and releasing the potential of people and companies.

Frances Abeton is the co-founder and CEO of WHYZE Health, a pioneering real-world evidence (RWE) company transforming how data is used to drive impact in clinical care and research. With over 20 years of leadership experience in healthcare, data science, and digital innovation, Frances is recognised for her strategic vision, cross-sector expertise, and commitment to patient-centred outcomes. She has a strong track record in scaling high-growth ventures, leading organisations from early-stage development to international commercialisation. At WHYZE Health, Frances has spearheaded partnerships with leading patient groups, healthcare systems and life sciences companies across the UK, EU, and U.S. markets. Her work has helped accelerate access to innovative treatments, unlock new revenue models, and position WHYZE Health as a trusted platform in the real-world data space.

Drew Applefield is a seasoned biotechnology professional with nearly two decades of diverse experience spanning research, consulting, investing, and business development. Currently serving as Director of Search & Evaluation at Sanofi, Drew leverages his extensive background to scout for innovative platform technologies that could drive future therapeutic advancements, with a specific focus on cell and gene therapies.

Drew holds a PhD in Biochemistry from Johns Hopkins University, and has previously held business development roles at Precision BioSciences, Eisai, and Legend Biotech.

Tom co-founded Clerkenwell Health in 2021. Tom's background is in the biopharmaceutical sector and includes 18 months at IQVIA. A graduate of the University of Bath, Tom serves as CEO of Clerkenwell.

Abby is the Regional Patient Engagement Lead EMEAC, Patient Innovation and Engagement, V&I Global Medical & Scientific Affairs at MSD. She is an experienced policy and strategy professional with a history of working in both government and the pharmaceutical industry. She has expertise in working with nonprofit organizations, strategic planning, government affairs, international relations and public policy. Abby earned a Masters Degree in Public Policy & Government from the Hebrew University of Jerusalem.

17 years of experience managing site operations across regulatory, source, finance, recruitment, and clinical workflows Oversees regulatory, eSource, eCRF data entry, contracts and budgets, as well as quality Masters in Pharmaceutical Sciences, Outcomes, and Policy Graduate certificate in Pharmaceutical Regulation Eagle Scout and enjoys sharing that experience with his twin sons

Tega Naomi Ayerume is an early-career clinical research professional and MSc Clinical Trials graduate from University College London (UCL), where she earned a Distinction. She currently works within NHS oncology trial operations, focusing on site-level study delivery and feasibility. She has supported oncology clinical trials across two major London NHS hospital sites and has also worked with a sponsor organisation, giving her a well-rounded perspective of trial delivery from both site and sponsor viewpoints.  This summer, Tega will begin a PhD in Clinical Trial Methodology at Queen Mary University of London. Her research will explore pilot and feasibility studies for online clinical trials, with the goal of developing methodological guidance for trialists. Tega brings both academic insight and site-level operational experience to her work, with a particular interest in patient engagement, innovation in trial design, and inclusive research practices.

Jeff Huntsman is the Chief Commercial Officer for PCM Trials and EmVenio Research, overseeing commercial strategy and revenue growth. Mr. Huntsman joined PCM Trials in 2024 with more than 30 years of experience in the Life Sciences space, where he has led global commercial teams selling pharma services solutions across the clinical development and regulatory lifecycle.

Prior to joining PCM Trials, Mr. Huntsman ran a consulting firm providing strategic advice to private equity, venture capital and emerging growth companies. Earlier in his career, he was the Chief Commercial Officer at Sitero, Citeline, ConnectiveRx, and LIQUENT. He has held executive leadership roles at Clarivate, Parexel, Thomson Reuters, and Rogers Communications as well as having served as a Health Care Advisor at Warburg Pincus and Growth Capital Partners.

Alex brings over 17 years of experience in the pharmaceutical industry, specializing in clinical technology at tech vendors, CROs, and pharmaceutical companies. His experience spans clinical and operational data, with deep experience in IRT, EDC, eCOA, eTMF, CTMS, SSU and a range of data and analytics platforms. At Jazz, he is responsible for overseeing the Clinical Data Factory and integration strategy as well as other AI and technology initiatives for the Global Clinical Development Operations team. He is focused on pulling in large amounts of data from different sources into an accurate and easily digestible format, collaborating with the Data Management, Clinical Operations, and RBQM teams at Jazz to align with business priorities. Alex is passionate about streamlining data movement and leveraging technology to simplify and accelerate processes across the clinical trial ecosystem.

Puneet Tyagi, PhD, is an Associate Director in the Dosage Form Design and Development group at AstraZeneca, based in Maryland, USA. His work focuses on the design and development of biologic formulations, with emphasis on long-acting injectables, transdermal systems, and oral delivery. His recent work involves advancing mRNA CMC strategies to enable rapid response to emerging infectious diseases and other high-impact indications. He plays a key role in advancing innovative drug delivery technologies and enabling translation from early discovery to clinical development.

Puneet earned his PhD in Pharmaceutical Sciences from the University of Colorado, after completing his bachelor’s and master’s degrees in India. He is a co-inventor on several U.S. and international patents and has published extensively in the areas of drug delivery and formulation science. With over 15 years of experience in pharmaceutical R&D, Puneet contributes strategically to AstraZeneca’s pipeline by driving innovation in formulation platforms and patient-centric delivery approaches.

Valerie Reynaert is the Head of Global Clinical Operations at Immunocore, a position she has held since April 2023. With over 20 years of experience in clinical development and operations, Valerie has established herself as a leader in the field of Vaccines and Pharmaceuticals development across Europe and the US. Her extensive career includes various leadership roles where she has driven significant advancements in clinical research and development. Valerie holds a Master's degree in Medical and Social Sciences from the Catholic University of Leuven, Belgium. Her academic background, combined with her professional expertise, has equipped her with a deep understanding of the complexities and challenges in clinical operations. Residing in the Philadelphia area, Valerie continues to contribute to the field with her innovative approach and dedication to improving global health outcomes. At Immunocore, she is committed to radically improving outcomes for patients with cancer, infectious diseases, and autoimmune diseases by pioneering and delivering transformative immunomodulating medicines.